Clinical Features and Treatment Strategies of Hepatocellular Carcinoma Associated with Non-alcoholic Fatty Liver Disease
DOI:
https://doi.org/10.54097/tnqp9z89Keywords:
Non-alcoholic fatty liver disease; Hepatocellular Carcinoma; Clinical Features; Treatment.Abstract
In recent years, non-alcoholic fatty liver disease (NAFLD) has become one of the chronic liver diseases with a high incidence rate in today's world. Its fast development is caused by the wide spread of related risk factors such as metabolism, obesity, type 2 diabetes, and metabolic syndrome, which is the main reason for its fast development. It is a very important topic among the topics in public health, and it is also an important topic that medicine of the modern world must explore. This rise coincides with the growing prevalence of metabolic cause of chronic liver disease across diverse populations. Alongside the rise in underlying diseases like obesity, diabetes, and metabolic syndrome, its prevalence has been rising quickly. Compared with HCC related to traditional viral hepatitis B/C and alcoholic liver disease, NAFLD-related HCC has different epidemiological characteristics and clinical backgrounds. It has insidious early symptoms and is extremely difficult to screen, leading to most patients being diagnosed at the middle or advanced stage and missing the best treatment opportunity. Currently, the main treatment methods for hepatocellular carcinoma (HCC) are still classical methods such as resection, transplant, immunotherapy, and so on. However, it has large deficiencies in clinical efficiency and safety. This article will, based on existing literature, state the clinical features, treatment strategies, future challenges and difficulties of NAFLD-HCC, and analyze its limitations and advantages, aiming to summarize and optimize its clinical features and treatment strategies.
Downloads
References
[1] Younossi, Zobair M., et al. “Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention.” Nature Reviews Gastroenterology & Hepatology, vol. 15, no. 1, 2018, pp. 11–20.
[2] He, Xin, et al. “Prognosis after Hepatic Resection of Patients with Hepatocellular Carcinoma Related to Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.” Frontiers in Oncology, vol. 13, 2023, Article 1100425. PMC
[3] Tan, D. J. H., Ng, C. H., Lin, S. Y., Pan, X. H., Tay, P., Lim, W. H., ... & Huang, D. Q. (2022). Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology, 23(4), 521-530
[4] Yang, Jason D., et al. “Outcomes in Liver Transplant Recipients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Results from the US Multicenter HCC Transplant Consortium.” Liver Transplantation, vol. 29, no. 2, 2023, pp. 179–191. PubMed
[5] Kutlu, Omer, et al. “Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma: A Multicenter Analysis.” HPB, vol. 21, no. 9, 2019, pp. 1230–1237. PubMed,
[6] Piscaglia, Fabio, et al. “Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease.” World Journal of Gastroenterology, vol. 22, no. 37, 2016, pp. 8294–8305. WJG,
[7] Guo, Wen et al. “Diet and Risk of Non-Alcoholic Fatty Liver Disease, Cirrhosis, and Liver Cancer: A Large Prospective Cohort Study in UK Biobank.” Nutrients vol. 14,24 5335. 15 Dec. 2022, doi:10.3390/nu14245335
[8] Powell, Elizabeth E et al. “Non-alcoholic fatty liver disease.” Lancet (London, England) vol. 397,10290 (2021): 2212-2224. doi:10.1016/S0140-6736(20)32511-3
[9] Llovet, Josep M et al. “Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.” Nature reviews. Gastroenterology & hepatology vol. 20,8 (2023): 487-503. doi:10.1038/s41575-023-00754-7
[10] Wang, Bo, et al. “Metabolic Dysfunction-Associated Fatty Liver Disease Increases the Risk of Complications after Radical Resection in Patients with Hepatocellular Carcinoma.” World Journal of Surgical Oncology, vol. 22, 2024, Article 198. BioMed Central
[11] Weinmann, A., Alt, Y., Koch, S., Nelles, C., Düber, C., Lang, H., ... & Schattenberg, J. M. (2015). Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC cancer, 15(1), 210.
[12] [12] Loomba, Rohit et al. “Mechanisms and disease consequences of nonalcoholic fatty liver disease.” Cell vol. 184,10 (2021): 2537-2564. doi:10.1016/j.cell.2021.04.015
[13] Teng, Y. X., Xie, S., Guo, P. P., Deng, Z. J., Zhang, Z. Y., Gao, W., ... & Zhong, J. H. (2022). Hepatocellular carcinoma in non-alcoholic fatty liver disease: current progresses and challenges. Journal of Clinical and Translational Hepatology, 10(5), 955.
[14] Degasperi, E., & Colombo, M. (2016). Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. The lancet Gastroenterology & hepatology, 1(2), 156-164.
[15] Wong, C. R., Nguyen, M. H., & Lim, J. K. (2016). Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World journal of gastroenterology, 22(37), 8294.
[16] Zhu, Andrew X., et al. “Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial.” The Lancet Oncology, vol. 19, no. 7, 2020, pp. 940–952. DOI:10.1016/S1470-2045(18)30351-6.
[17] Finn, Richard S., et al. “Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.” The New England Journal of Medicine, vol. 382, no. 20, 2020, pp. 1894–1905. DOI:10.1056/NEJMoa1915745.
[18] Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol. 2022 Jan 21;28(3):310-331.
[19] Kudo, Masatoshi, et al. “Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma (REFLECT): A Randomised, Open-Label, Non-Inferiority Phase 3 Trial.” The Lancet, vol. 391, no. 10126, 2018, pp. 1163–1173. DOI:10.1016/S0140-6736(18)30207-1.
[20] Grgurevic, I., Bozin, T., Mikus, M., Kukla, M., & O’Beirne, J. (2021). Hepatocellular carcinoma in non-alcoholic fatty liver disease: from epidemiology to diagnostic approach. Cancers, 13(22), 5844.
[21] Foerster, Friedrich et al. “NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.” Journal of hepatology vol. 76,2 (2022): 446-457. doi:10.1016/j.jhep.2021.09.007
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
